A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2012 by Alexandra Marine and General Hospital
Sponsor:
Information provided by (Responsible Party):
Craig Hudson MD, Alexandra Marine and General Hospital
ClinicalTrials.gov Identifier:
NCT01684475
First received: September 11, 2012
Last updated: September 12, 2012
Last verified: September 2012
  Purpose

The purpose of this study is to assess the ability of CJH1 to increase the sensitivity of dopamine receptors and thereby reduce symptoms of Parkinson's Disease.


Condition Intervention Phase
Parkinson's Disease
Drug: CJH1 (CLR4001)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASE

Resource links provided by NLM:


Further study details as provided by Alexandra Marine and General Hospital:

Primary Outcome Measures:
  • Reduced signs and symptoms of Parkinson's disease [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    Reduced signs and symptoms of Parkinson's disease


Estimated Enrollment: 21
Study Start Date: September 2012
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment with CJH1 Drug: CJH1 (CLR4001)

  Eligibility

Ages Eligible for Study:   40 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient's with Parkinson's disease

Exclusion Criteria:

  • Contraindications to study medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01684475

Locations
Canada, Ontario
Gateway Rural Health Research Recruiting
Goderich, Ontario, Canada, N7A 1W5
Contact: Craig Hudson, MD    519-524-8323      
Principal Investigator: Craig J Hudson, MD         
Sponsors and Collaborators
Alexandra Marine and General Hospital
  More Information

No publications provided

Responsible Party: Craig Hudson MD, Psychiatrist, Alexandra Marine and General Hospital
ClinicalTrials.gov Identifier: NCT01684475     History of Changes
Other Study ID Numbers: CJH1 Trial
Study First Received: September 11, 2012
Last Updated: September 12, 2012
Health Authority: Canada: Health Canada

Keywords provided by Alexandra Marine and General Hospital:
Novel Treatment Parkinson's disease

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on August 21, 2014